Healthcare ❯ Pharmaceuticals ❯ Biotechnology ❯ Drug Development
The deal gives Lilly a precision antibody‑degradation platform and a Phase 1 candidate that cut disease‑driving antibodies, signaling a push to broaden its immunology pipeline.
